Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration

NEW YORK, Jan. 25, 2011 Reportlinker.com announces that a new market research report is available in its catalogue:

The Future of In Vitro and In Vivo Diagnostic Integration

http://www.reportlinker.com/p0363597/The-Future-of-In-Vitro-and-In-Vivo-Diagnostic-Integration.html

The term in-vitro/in-vivo diagnostics (IV2D) describes the integration of molecular diagnostics with radiology and pathology (imaging), as well as new software and IT platforms. The aims of this integration are to improve patient care. This report provides an overview of current developments in integrated medical diagnostics, covering the emergence of new IV2D methods that combine IVD with current and developing imaging platforms. The drivers of this integration are reviewed including new disease biomarkers, single, combined and emerging imaging systems, as well as IT and patient-centred systems.

Scope of this research

- Assess the key technologies that will enable in vivo, in vitro diagnostic integration.

- Understand how IVD methods, biomarkers and imaging methods have been applied to challenges of diagnosis in breast cancer and Alzheimer's disease.

- Discover how centres of expertise, such as academic departments, are driving new discoveries and offering valuable alliances to diagnostic companies.

- Understand the factors that are driving healthcare providers to develop improved healthcare programmes through integration in medical diagnostics.

Research and analysis highlights

Today, diagnosis and treatment are increasingly integrated. This reflects developments in several key areas: scientific, diagnosis, evidence-based therapies, advancing personalized care and improved process efficiency. The need to improve patient diagnosis is today driving healthcare providers to improve management and process efficiency.

The rapidly evolving IV2D field offers important opportunities to diagnostic imaging companies. While imaging continues to see important refinements, the development of new imaging systems is challenging. In contrast, substantial numbers of in-vivo biomarkers are being discovered, offering combined "hybrid" integrations with imaging.

Siemens is a global provider of medical diagnostic systems, incorporating primary tests and instrumentation, IT platforms and software solutions, for clinical data handling and processing. Siemens is also developing technologies in the field of integrated diagnostics.

Key reasons to purchase this research

- What are the major imaging systems in diagnosis and how are they being applied to diagnosis in breast cancer and Alzheimer's disease?

- What are the business models of some of the major diagnostic companies as they establish new integrated diagnostic and healthcare capabilities?

- What levels of support and capability do healthcare providers seek from companies offering products and services in the fields of diagnostics?

- What strategies are the major diagnostic companies taking to reduce costs of the healthcare products and services?

- Why is it anticipated that the next decade will see substantial growth in the integrated diagnostics field?

To order this report:

: The Future of In Vitro and In Vivo Diagnostic Integration

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.